<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650311</url>
  </required_header>
  <id_info>
    <org_study_id>12-239</org_study_id>
    <nct_id>NCT01650311</nct_id>
  </id_info>
  <brief_title>Investigating Serotonin Signalling in IBD Patients</brief_title>
  <acronym>IBD</acronym>
  <official_title>Investigating Serotonin Signalling in IBD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alterations in normal serotonin (5-hydroxytryptamine;5-HT) signaling have been reported in
      ulcerative colitis (UC) and Crohn's disease (CD). Studies report an increase in
      enterochromaffin (EC) cell, main source of 5-HT in the gut, numbers in CD and UC patients.
      Up-regulated expression of mucosal Tryptophan hydroxylase (TPH)-1, catalytic enzyme in 5-HT
      production, messenger RNA (mRNA) have been found in CD patients in remission who are
      suffering the irritable bowel syndrome (IBS)-like symptoms. Alterations in normal 5-HT
      signaling has also been reported in animal models of inflammatory bowel disease (IBD). Thus,
      the aim of the proposed research project will be to study the alterations in 5-HT signalling
      accompanying GI inflammatory conditions, such as IBD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The gut produces approximately 95% of serotonin (5-hydroxytryptamine; 5-HT) found in the
      human body; where, it is a very important mucosal signaling molecule participating in gut
      motility, sensation, and secretion.The vast majority of the gut-derived 5-HT is produced by
      specialized epithelial cells of The GI tract, called enterochromaffin (EC) cells. EC cells
      produce 5-HT from dietary tryptophan, this process involves the rate limiting enzyme
      tryptophan hydroxylase (TPH) 1, once produced this 5-HT can be released into the gut lumen,
      surrounding tissue and can enter the blood circulation.5-HT mediates many gastrointestinal
      functions, including secretion and peristalsis, by acting on a diverse range of 5-HT
      receptors. Five of the seven known receptor families of 5-HT (5-HT1, 5-HT2, 5-HT3, 5-HT4 and
      5-HT7) are expressed in the gut.

      5-HT has been evaluated in IBD and in animal models of colitis. An increase in numbers of EC
      cells expressing 5-HT is observed in CD and UC patients and consumption of selective 5-HT
      reuptake inhibitors is associated with microscopic colitis. In the present study, we plan to
      investigate the key elements of mucosal 5-HT signaling in CD patients for a better
      understanding of the role of 5-HT in pathogenesis of IBD.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TPH1 and SERT expression</measure>
    <time_frame>At the time of sample collection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Receptor expressions</measure>
    <time_frame>At the time of sample collection</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy control group will include participants consenting prior to colorectal cancer screening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD patient groups</arm_group_label>
    <description>The patient groups will include patients with clinical diagnosis of CD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UC patient group</arm_group_label>
    <description>The patient groups will include patients with clinical diagnosis of UC.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples will be collected from inflamed and non-inflamed regions, spanning the distal colon
      to distal ileum.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All potential participants will be included only if they meet the stringent inclusion
        criteria in place. Only when their eligibility is confirmed the potential participants will
        be approached for consent prior to endoscopy. For healthy subjects, they will be screened
        and consented from the colorectal screening list, also prior to endoscopy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient groups: Disease diagnosis (CD or UC),duration of disease, previous/type of
             treatments, duration of treatment and disease prognosis.

          -  Healthy controls: No diagnosis of CD or UC and no diagnosis of IBS.

        Exclusion Criteria:

          -  Patient groups: Drugs that directly affect components of 5-HT signaling, any other
             disease or condition that may interfere with study assessments as judged by the
             investigator.

          -  Healthy controls:Chronic use of any anti-inflammatory drugs, drugs that directly
             affect components of 5-HT signalling and any other disease or condition that may
             interfere with study assessments as judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waliul I Khan, MBBS, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Pathology &amp; Molecular Medicine, McMaster University, Hamilton, Canada.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Marshall, MD, MSc, FRCPC, AGAF.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, McMaster University, Hamilton, Canada.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University Medical Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004 Jun;126(7):1657-64.</citation>
    <PMID>15188158</PMID>
  </reference>
  <reference>
    <citation>Minderhoud IM, Oldenburg B, Schipper ME, ter Linde JJ, Samsom M. Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission. Clin Gastroenterol Hepatol. 2007 Jun;5(6):714-20. Epub 2007 May 4.</citation>
    <PMID>17481962</PMID>
  </reference>
  <reference>
    <citation>El-Salhy M, Danielsson A, Stenling R, Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Intern Med. 1997 Nov;242(5):413-9.</citation>
    <PMID>9408072</PMID>
  </reference>
  <reference>
    <citation>Sharkey KA, Mawe GM. Neuroimmune and epithelial interactions in intestinal inflammation. Curr Opin Pharmacol. 2002 Dec;2(6):669-77. Review.</citation>
    <PMID>12482729</PMID>
  </reference>
  <reference>
    <citation>Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol. 2010 Jul 1;161(1):19-27. doi: 10.1111/j.1365-2249.2010.04150.x. Epub 2010 Apr 9. Review.</citation>
    <PMID>20408856</PMID>
  </reference>
  <reference>
    <citation>Buchan AM. Nutrient Tasting and Signaling Mechanisms in the Gut III. Endocrine cell recognition of luminal nutrients. Am J Physiol. 1999 Dec;277(6 Pt 1):G1103-7. Review.</citation>
    <PMID>10600808</PMID>
  </reference>
  <reference>
    <citation>Rindi G, Kl√∂ppel G. Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology. 2004;80 Suppl 1:12-5. Review.</citation>
    <PMID>15477709</PMID>
  </reference>
  <reference>
    <citation>Gordon JI, Schmidt GH, Roth KA. Studies of intestinal stem cells using normal, chimeric, and transgenic mice. FASEB J. 1992 Sep;6(12):3039-50. Review.</citation>
    <PMID>1521737</PMID>
  </reference>
  <reference>
    <citation>Lomax AE, Linden DR, Mawe GM, Sharkey KA. Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. Auton Neurosci. 2006 Jun 30;126-127:250-7. Epub 2006 Apr 17. Review.</citation>
    <PMID>16616704</PMID>
  </reference>
  <reference>
    <citation>Nagata K, Fujimiya M, Sugiura H, Uehara M. Intracellular localization of serotonin in mast cells of the colon in normal and colitis rats. Histochem J. 2001 Sep-Oct;33(9-10):559-68.</citation>
    <PMID>12005028</PMID>
  </reference>
  <reference>
    <citation>Bertrand PP, Bertrand RL. Serotonin release and uptake in the gastrointestinal tract. Auton Neurosci. 2010 Feb 16;153(1-2):47-57. doi: 10.1016/j.autneu.2009.08.002. Epub 2009 Sep 2. Review.</citation>
    <PMID>19729349</PMID>
  </reference>
  <reference>
    <citation>Spiller R. Serotonin and GI clinical disorders. Neuropharmacology. 2008 Nov;55(6):1072-80. doi: 10.1016/j.neuropharm.2008.07.016. Epub 2008 Jul 19. Review.</citation>
    <PMID>18687345</PMID>
  </reference>
  <reference>
    <citation>Belai A, Boulos PB, Robson T, Burnstock G. Neurochemical coding in the small intestine of patients with Crohn's disease. Gut. 1997 Jun;40(6):767-74.</citation>
    <PMID>9245931</PMID>
  </reference>
  <reference>
    <citation>Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Mawe G, Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil. 2005 Dec;17(6):863-70.</citation>
    <PMID>16336502</PMID>
  </reference>
  <reference>
    <citation>Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord. 2003;3 Suppl 2:S25-34. Review.</citation>
    <PMID>12776000</PMID>
  </reference>
  <reference>
    <citation>Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol. 2000 Oct;95(10):2698-709. Review.</citation>
    <PMID>11051338</PMID>
  </reference>
  <reference>
    <citation>Oshima S, Fujimura M, Fukimiya M. Changes in number of serotonin-containing cells and serotonin levels in the intestinal mucosa of rats with colitis induced by dextran sodium sulfate. Histochem Cell Biol. 1999 Oct;112(4):257-63.</citation>
    <PMID>10550609</PMID>
  </reference>
  <reference>
    <citation>Linden DR, Chen JX, Gershon MD, Sharkey KA, Mawe GM. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2003 Jul;285(1):G207-16. Epub 2003 Mar 19.</citation>
    <PMID>12646422</PMID>
  </reference>
  <reference>
    <citation>Yang GB, Lackner AA. Proximity between 5-HT secreting enteroendocrine cells and lymphocytes in the gut mucosa of rhesus macaques (Macaca mulatta) is suggestive of a role for enterochromaffin cell 5-HT in mucosal immunity. J Neuroimmunol. 2004 Jan;146(1-2):46-9.</citation>
    <PMID>14698846</PMID>
  </reference>
  <reference>
    <citation>Wang H, Steeds J, Motomura Y, Deng Y, Verma-Gandhu M, El-Sharkawy RT, McLaughlin JT, Grencis RK, Khan WI. CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut. 2007 Jul;56(7):949-57. Epub 2007 Feb 15.</citation>
    <PMID>17303597</PMID>
  </reference>
  <reference>
    <citation>Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J Pediatr Gastroenterol Nutr. 2007 Dec;45 Suppl 2:S115-9. doi: 10.1097/MPG.0b013e31812e66da. Review.</citation>
    <PMID>18185071</PMID>
  </reference>
  <reference>
    <citation>Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007 Jan;132(1):397-414. Review.</citation>
    <PMID>17241888</PMID>
  </reference>
  <reference>
    <citation>Idzko M, Panther E, Stratz C, M√ºller T, Bayer H, Zissel G, D√ºrk T, Sorichter S, Di Virgilio F, Geissler M, Fiebich B, Herouy Y, Elsner P, Norgauer J, Ferrari D. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. J Immunol. 2004 May 15;172(10):6011-9.</citation>
    <PMID>15128784</PMID>
  </reference>
  <reference>
    <citation>Le√≥n-Ponte M, Ahern GP, O'Connell PJ. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood. 2007 Apr 15;109(8):3139-46. Epub 2006 Dec 7.</citation>
    <PMID>17158224</PMID>
  </reference>
  <reference>
    <citation>Meredith EJ, Chamba A, Holder MJ, Barnes NM, Gordon J. Close encounters of the monoamine kind: immune cells betray their nervous disposition. Immunology. 2005 Jul;115(3):289-95. Review.</citation>
    <PMID>15946246</PMID>
  </reference>
  <reference>
    <citation>Young MR, Matthews JP. Serotonin regulation of T-cell subpopulations and of macrophage accessory function. Immunology. 1995 Jan;84(1):148-52.</citation>
    <PMID>7890297</PMID>
  </reference>
  <reference>
    <citation>Ghia JE, Li N, Wang H, Collins M, Deng Y, El-Sharkawy RT, C√¥t√© F, Mallet J, Khan WI. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology. 2009 Nov;137(5):1649-60. doi: 10.1053/j.gastro.2009.08.041. Epub 2009 Aug 23.</citation>
    <PMID>19706294</PMID>
  </reference>
  <reference>
    <citation>Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2(3):541-6.</citation>
    <PMID>17406617</PMID>
  </reference>
  <reference>
    <citation>Costedio MM, Hyman N, Mawe GM. Serotonin and its role in colonic function and in gastrointestinal disorders. Dis Colon Rectum. 2007 Mar;50(3):376-88. Review.</citation>
    <PMID>17195902</PMID>
  </reference>
  <reference>
    <citation>Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, B√ºrgel N, Fromm M, Zeitz M, Fuss I, Strober W, Schulzke JD. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005 Aug;129(2):550-64.</citation>
    <PMID>16083712</PMID>
  </reference>
  <reference>
    <citation>Kidd M, Gustafsson BI, Drozdov I, Modlin IM. IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease. Neurogastroenterol Motil. 2009 Apr;21(4):439-50. doi: 10.1111/j.1365-2982.2008.01210.x. Epub 2008 Oct 25.</citation>
    <PMID>19019013</PMID>
  </reference>
  <reference>
    <citation>Bishop AE, Pietroletti R, Taat CW, Brummelkamp WH, Polak JM. Increased populations of endocrine cells in Crohn's ileitis. Virchows Arch A Pathol Anat Histopathol. 1987;410(5):391-6.</citation>
    <PMID>3103321</PMID>
  </reference>
  <reference>
    <citation>Khan WI, Motomura Y, Wang H, El-Sharkawy RT, Verdu EF, Verma-Gandhu M, Rollins BJ, Collins SM. Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G803-11. Epub 2006 May 25.</citation>
    <PMID>16728728</PMID>
  </reference>
  <reference>
    <citation>Nakajima M, Shiihara Y, Shiba Y, Sano I, Sakai T, Mizumoto A, Itoh Z. Effect of 5-hydroxytryptamine on gastrointestinal motility in conscious guinea-pigs. Neurogastroenterol Motil. 1997 Dec;9(4):205-14.</citation>
    <PMID>9430788</PMID>
  </reference>
  <reference>
    <citation>Li N, Ghia JE, Wang H, McClemens J, Cote F, Suehiro Y, Mallet J, Khan WI. Serotonin activates dendritic cell function in the context of gut inflammation. Am J Pathol. 2011 Feb;178(2):662-71. doi: 10.1016/j.ajpath.2010.10.028.</citation>
    <PMID>21281798</PMID>
  </reference>
  <reference>
    <citation>Magro F, Vieira-Coelho MA, Fraga S, Serr√£o MP, Veloso FT, Ribeiro T, Soares-da-Silva P. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci. 2002 Jan;47(1):216-24.</citation>
    <PMID>11837726</PMID>
  </reference>
  <reference>
    <citation>Wong JM, Wei SC. Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease. J Formos Med Assoc. 2003 Sep;102(9):613-9.</citation>
    <PMID>14625605</PMID>
  </reference>
  <reference>
    <citation>Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Grundy D, Tonini M, De Ponti F, Corinaldesi R, Barbara G. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol. 2011 Jul;106(7):1290-8. doi: 10.1038/ajg.2011.86. Epub 2011 Mar 22.</citation>
    <PMID>21427712</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBD, CD, UC, Serotonin, 5-HT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

